News from the MS Foundation:
Investigators at several centers
nationwide are recruiting 172 people with relapsing-remitting MS to compare the
effectiveness of the current recommended amount of vitamin D supplementation
versus high dose vitamin D supplementation at reducing MS disease activity,
when added to standard therapy with glatiramer acetate (Copaxone®, Teva
Pharmaceutical Industries).
nationwide are recruiting 172 people with relapsing-remitting MS to compare the
effectiveness of the current recommended amount of vitamin D supplementation
versus high dose vitamin D supplementation at reducing MS disease activity,
when added to standard therapy with glatiramer acetate (Copaxone®, Teva
Pharmaceutical Industries).
To learn more about the
enrollment criteria for this study, and to find out if you are eligible to
participate, please see: http://www.clinicaltrials.gov/ct2/show/NCT01490502,
or e-mail [email protected]
..
Comments are appreciated. Note that All comments are moderated
If not yet receiving our weekly e-Newsletter – Click here to: REGISTER –
so that you can be kept up to date with MS News and Information
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIKE this BLOG? – Please click the LIKE button top left
so that you can be kept up to date with MS News and Information
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
LIKE this BLOG? – Please click the LIKE button top left
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews